ACR Appropriateness Criteria ® Resectable Pancreatic Cancer

William E. Jones, W. Waren Suh, May Abdel-Wahab, Ross A. Abrams, Nilofer Azad, Prajnan Das, Jadranka Dragovic, Karyn A. Goodman, Salma Jabbour, Andre A. Konski, Albert C. Koong, Rachit Kumar, Percy Lee, Timothy M. Pawlik, William Small, Joseph M. Herman

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Management of resectable pancreatic adenocarcinoma continues to present a challenge due to a paucity of high-quality randomized studies. Administration of adjuvant chemotherapy is widely accepted due to the high risk of systemic spread associated with pancreatic adenocarcinoma, but the role of radiation therapy is less clear. This paper reviews literature associated with resectable pancreatic cancer to include prognostic factors to aid in the selection of patients appropriate for adjuvant therapies. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.

Original languageEnglish (US)
Pages (from-to)109-117
Number of pages9
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume40
Issue number2
DOIs
StatePublished - Jan 1 2017

Fingerprint

Pancreatic Neoplasms
Adenocarcinoma
Guidelines
Expert Testimony
Adjuvant Chemotherapy
Radiology
Patient Selection
Radiotherapy
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Keywords

  • Appropriateness criteria
  • adjuvant therapy
  • resectable pancreatic adenocarcinoma

Cite this

Jones, W. E., Suh, W. W., Abdel-Wahab, M., Abrams, R. A., Azad, N., Das, P., ... Herman, J. M. (2017). ACR Appropriateness Criteria ® Resectable Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 40(2), 109-117. https://doi.org/10.1097/COC.0000000000000370
Jones, William E. ; Suh, W. Waren ; Abdel-Wahab, May ; Abrams, Ross A. ; Azad, Nilofer ; Das, Prajnan ; Dragovic, Jadranka ; Goodman, Karyn A. ; Jabbour, Salma ; Konski, Andre A. ; Koong, Albert C. ; Kumar, Rachit ; Lee, Percy ; Pawlik, Timothy M. ; Small, William ; Herman, Joseph M. / ACR Appropriateness Criteria ® Resectable Pancreatic Cancer. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2017 ; Vol. 40, No. 2. pp. 109-117.
@article{f8591eb133214dd887048155c4e59da7,
title = "ACR Appropriateness Criteria {\circledR} Resectable Pancreatic Cancer",
abstract = "Management of resectable pancreatic adenocarcinoma continues to present a challenge due to a paucity of high-quality randomized studies. Administration of adjuvant chemotherapy is widely accepted due to the high risk of systemic spread associated with pancreatic adenocarcinoma, but the role of radiation therapy is less clear. This paper reviews literature associated with resectable pancreatic cancer to include prognostic factors to aid in the selection of patients appropriate for adjuvant therapies. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.",
keywords = "Appropriateness criteria, adjuvant therapy, resectable pancreatic adenocarcinoma",
author = "Jones, {William E.} and Suh, {W. Waren} and May Abdel-Wahab and Abrams, {Ross A.} and Nilofer Azad and Prajnan Das and Jadranka Dragovic and Goodman, {Karyn A.} and Salma Jabbour and Konski, {Andre A.} and Koong, {Albert C.} and Rachit Kumar and Percy Lee and Pawlik, {Timothy M.} and William Small and Herman, {Joseph M.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1097/COC.0000000000000370",
language = "English (US)",
volume = "40",
pages = "109--117",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

Jones, WE, Suh, WW, Abdel-Wahab, M, Abrams, RA, Azad, N, Das, P, Dragovic, J, Goodman, KA, Jabbour, S, Konski, AA, Koong, AC, Kumar, R, Lee, P, Pawlik, TM, Small, W & Herman, JM 2017, 'ACR Appropriateness Criteria ® Resectable Pancreatic Cancer', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 40, no. 2, pp. 109-117. https://doi.org/10.1097/COC.0000000000000370

ACR Appropriateness Criteria ® Resectable Pancreatic Cancer. / Jones, William E.; Suh, W. Waren; Abdel-Wahab, May; Abrams, Ross A.; Azad, Nilofer; Das, Prajnan; Dragovic, Jadranka; Goodman, Karyn A.; Jabbour, Salma; Konski, Andre A.; Koong, Albert C.; Kumar, Rachit; Lee, Percy; Pawlik, Timothy M.; Small, William; Herman, Joseph M.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 40, No. 2, 01.01.2017, p. 109-117.

Research output: Contribution to journalReview article

TY - JOUR

T1 - ACR Appropriateness Criteria ® Resectable Pancreatic Cancer

AU - Jones, William E.

AU - Suh, W. Waren

AU - Abdel-Wahab, May

AU - Abrams, Ross A.

AU - Azad, Nilofer

AU - Das, Prajnan

AU - Dragovic, Jadranka

AU - Goodman, Karyn A.

AU - Jabbour, Salma

AU - Konski, Andre A.

AU - Koong, Albert C.

AU - Kumar, Rachit

AU - Lee, Percy

AU - Pawlik, Timothy M.

AU - Small, William

AU - Herman, Joseph M.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Management of resectable pancreatic adenocarcinoma continues to present a challenge due to a paucity of high-quality randomized studies. Administration of adjuvant chemotherapy is widely accepted due to the high risk of systemic spread associated with pancreatic adenocarcinoma, but the role of radiation therapy is less clear. This paper reviews literature associated with resectable pancreatic cancer to include prognostic factors to aid in the selection of patients appropriate for adjuvant therapies. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.

AB - Management of resectable pancreatic adenocarcinoma continues to present a challenge due to a paucity of high-quality randomized studies. Administration of adjuvant chemotherapy is widely accepted due to the high risk of systemic spread associated with pancreatic adenocarcinoma, but the role of radiation therapy is less clear. This paper reviews literature associated with resectable pancreatic cancer to include prognostic factors to aid in the selection of patients appropriate for adjuvant therapies. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.

KW - Appropriateness criteria

KW - adjuvant therapy

KW - resectable pancreatic adenocarcinoma

UR - http://www.scopus.com/inward/record.url?scp=85013683945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013683945&partnerID=8YFLogxK

U2 - 10.1097/COC.0000000000000370

DO - 10.1097/COC.0000000000000370

M3 - Review article

VL - 40

SP - 109

EP - 117

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 2

ER -